CA2339991A1 - Microemulsions as solid dosage forms for oral administration - Google Patents

Microemulsions as solid dosage forms for oral administration Download PDF

Info

Publication number
CA2339991A1
CA2339991A1 CA002339991A CA2339991A CA2339991A1 CA 2339991 A1 CA2339991 A1 CA 2339991A1 CA 002339991 A CA002339991 A CA 002339991A CA 2339991 A CA2339991 A CA 2339991A CA 2339991 A1 CA2339991 A1 CA 2339991A1
Authority
CA
Canada
Prior art keywords
dosage forms
microemulsions
solid dosage
oral administration
drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002339991A
Other languages
French (fr)
Other versions
CA2339991C (en
Inventor
S. Indiran Pather
Sangeeta V. Gupte
Rajendra K. Khankari
John Hontz
Ramya Kumbale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cima Labs Inc
Original Assignee
Cima Labs Inc.
S. Indiran Pather
Sangeeta V. Gupte
Rajendra K. Khankari
John Hontz
Robinson, Joseph R.
Eichman, Jonathan D.
Ramya Kumbale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cima Labs Inc., S. Indiran Pather, Sangeeta V. Gupte, Rajendra K. Khankari, John Hontz, Robinson, Joseph R., Eichman, Jonathan D., Ramya Kumbale filed Critical Cima Labs Inc.
Publication of CA2339991A1 publication Critical patent/CA2339991A1/en
Application granted granted Critical
Publication of CA2339991C publication Critical patent/CA2339991C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds

Abstract

Novel pharmaceutical compositions which improve the rate and/or extent of absorption of drugs are disclosed. The novel pharmaceutical compositions of the present invention comprise drug-containing microemulsions adsorbed onto solid particles which may be further formulated into solid dosage forms. The compositions and dosage forms of the present invention improve the bioavailability of the wide range of drugs including drugs that are known or suspected of having poor bioavailability by the utilization of several different mechanisms.
CA002339991A 1998-08-13 1999-08-13 Microemulsions as solid dosage forms for oral administration Expired - Fee Related CA2339991C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9634798P 1998-08-13 1998-08-13
US60/096,347 1998-08-13
PCT/US1999/018552 WO2000009093A1 (en) 1998-08-13 1999-08-13 Microemulsions as solid dosage forms for oral administration

Publications (2)

Publication Number Publication Date
CA2339991A1 true CA2339991A1 (en) 2000-02-24
CA2339991C CA2339991C (en) 2007-01-02

Family

ID=22256941

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002339991A Expired - Fee Related CA2339991C (en) 1998-08-13 1999-08-13 Microemulsions as solid dosage forms for oral administration

Country Status (9)

Country Link
US (1) US6280770B1 (en)
EP (2) EP2127642A3 (en)
JP (1) JP4815053B2 (en)
AT (1) ATE462417T1 (en)
AU (1) AU5486899A (en)
CA (1) CA2339991C (en)
DE (1) DE69942205D1 (en)
ES (1) ES2341510T3 (en)
WO (1) WO2000009093A1 (en)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858401A (en) * 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6350470B1 (en) * 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
US6793934B1 (en) 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
AUPQ573300A0 (en) * 2000-02-21 2000-03-16 Australian Nuclear Science & Technology Organisation Controlled release ceramic particles, compositions thereof, processes of preparation and methods of use
GB0008785D0 (en) * 2000-04-10 2000-05-31 Novartis Ag Organic compounds
EP1318790A4 (en) * 2000-09-19 2006-02-01 Cima Labs Inc Pharmaceutical compositions for rectal and vaginal administration
US7799342B2 (en) * 2000-12-06 2010-09-21 Wyeth Llc Fast dissolving tablet
WO2002083102A1 (en) * 2001-02-23 2002-10-24 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
US6692771B2 (en) * 2001-02-23 2004-02-17 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
MXPA03010165A (en) * 2001-06-22 2004-03-10 Pfizer Prod Inc Pharmaceutical compositions of adsorbates of amorphous drug.
US20030068356A1 (en) 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
ITMI20011756A1 (en) * 2001-08-09 2003-02-09 Remedia S R L PHARMACEUTICAL COMPOSITION INCLUDING A DOUBLE WATER / OIL / WATER MICROEMULSION INCORPORATED IN A SOLID SUPPORT
US20030083286A1 (en) * 2001-08-22 2003-05-01 Ching-Leou Teng Bioadhesive compositions and methods for enhanced intestinal drug absorption
US20030124196A1 (en) * 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
EA008072B1 (en) * 2001-12-03 2007-02-27 Новацея, Инк. Pharmaceutical compositions comprising active vitamin d compounds
ITMI20012694A1 (en) * 2001-12-19 2003-06-19 Remedia S R L PHARMACEUTICAL COMPOSITION INCLUDING A DOUBLE OIL / WATER / OIL MICROEMULSION INCORPORATED IN A SOLID SUPPORT
CA2474838C (en) 2002-02-01 2009-01-06 Pfizer Products Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
ITMI20021392A1 (en) * 2002-06-25 2003-12-29 Nicox Sa PHARMACEUTICAL FORMS FOR THE ORAL ADMINISTRATION OF LIQUID DRUGS AT AMBIENT TEMPERATURE EQUIPPED WITH BETTER BIOAVAILABILITY
CN100515388C (en) * 2002-06-26 2009-07-22 金拓 Solid dosage forms for rapid dissolution of poorly soluble drugs
US20040115226A1 (en) * 2002-12-12 2004-06-17 Wenji Li Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same
FR2851918B1 (en) * 2003-03-06 2006-06-16 IMPREGNATED POWDER ENHANCING BIOAVAILABILITY AND / OR SOLUBILITY AND METHOD OF MANUFACTURE
ATE540671T1 (en) * 2003-08-04 2012-01-15 Bend Res Inc PHARMACEUTICAL COMPOSITIONS OF AMORPHOUS DRUG ADSORBATES AND LIPOPHILIC MICROPHASE-FORMING MATERIALS
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
EP1715853A4 (en) * 2004-02-17 2012-07-18 Transcept Pharmaceuticals Inc Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
US20050220866A1 (en) * 2004-04-02 2005-10-06 Dr. Reddy's Laboratories Limited Novel capsule formulations of etoposide for oral use
US20050238675A1 (en) * 2004-04-26 2005-10-27 Wenjie Li Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
CA2578356C (en) 2004-09-24 2013-05-28 Boehringer Ingelheim Pharmaceuticals, Inc. A new class of surfactant-like materials
US20090169583A1 (en) * 2005-02-08 2009-07-02 Pfizer, Inc. Solid Adsorbates of Hydrophobic Drugs
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
WO2006113505A2 (en) 2005-04-15 2006-10-26 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US8242131B2 (en) * 2005-05-25 2012-08-14 Transcept Pharmaceuticals, Inc. Methods of treating middle-of-the-night insomnia
US20070287740A1 (en) * 2005-05-25 2007-12-13 Transcept Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
US20070225322A1 (en) * 2005-05-25 2007-09-27 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the night insomnia
JP5050322B2 (en) * 2005-06-21 2012-10-17 三菱化学株式会社 Oil-containing solid and method for producing the same
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
WO2008063910A2 (en) * 2006-11-08 2008-05-29 Novavax, Inc. Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
WO2008091588A1 (en) 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
WO2008135855A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
WO2008135828A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US8974827B2 (en) 2007-06-04 2015-03-10 Bend Research, Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
US20090060993A1 (en) * 2007-09-04 2009-03-05 Joseph Schwarz Solid pharmaceutical composition for enhanced delivery of coenzyme q-10 and ubiquinones
WO2009073215A1 (en) 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
US9233078B2 (en) 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
GB0724279D0 (en) * 2007-12-12 2008-01-23 Photocure Asa Use
EP2111854A1 (en) 2008-04-22 2009-10-28 Lek Pharmaceuticals D.D. Self-microemulsifying systems incorporated into liquid core microcapsules
JP5661630B2 (en) * 2008-09-09 2015-01-28 シマ ラブス インク． Weak ionic compound dosage forms
CA2750216A1 (en) * 2008-12-15 2010-07-08 Fleming And Company, Pharmaceuticals Rapidly dissolving vitamin formulation and methods of using the same
KR101004205B1 (en) * 2008-12-17 2010-12-24 동아제약주식회사 The controlled released pharmaceutical compsitions of udenafil for sustained release property
CA2763837A1 (en) * 2009-06-11 2010-12-16 Photocure Asa Solid compositions comprising 5-aminolevulinic acid
ES2385240B1 (en) 2010-07-26 2013-09-23 Gp-Pharm, S.A. CAPSULES OF ACTIVE PHARMACEUTICAL PRINCIPLES AND POLYINSATURATED FATTY ACIDS FOR THE TREATMENT OF PROSTATE DISEASES.
US20120213855A1 (en) * 2011-02-17 2012-08-23 Cima Labs Inc. Dosage forms for weakly ionizable compounds
US20170325481A1 (en) * 2011-06-28 2017-11-16 Kemin Industries, Inc. Method of forming encapsulated compositions with enhanced solubility and stability
US20130004619A1 (en) * 2011-06-28 2013-01-03 Kemin Industries, Inc. Method of Forming Encapsulated Compositions with Enhanced Solubility and Stability
JP6384964B2 (en) 2012-10-30 2018-09-05 ネクター セラピューティクス Solid salts of α-6-MPEG6-O-hydroxycodone as opioid agonists and uses thereof
KR102237799B1 (en) 2012-11-14 2021-04-08 더블유.알. 그레이스 앤드 캄파니-콘. Compositions containing a biologically active material and a non-ordered inorganic oxide
WO2014096139A1 (en) * 2012-12-20 2014-06-26 Solural Pharma ApS Solid oral dosage form of testosterone derivative
WO2014128564A2 (en) 2013-02-21 2014-08-28 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
WO2015100406A1 (en) 2013-12-26 2015-07-02 Clarus Therapeutics, Inc. Use of oral pharmaceutical products combining testosterone esters with hypolipidemic agents
EA036836B1 (en) * 2014-06-19 2020-12-25 Солурал Фарма Апс Pharmaceutical composition for providing lymphatic absorption of lipophilic compounds in fed and in fasted state
CA2958696C (en) 2014-08-28 2022-09-06 Board Of Regents, The University Of Texas System Formulations of testosterone and methods of treatment therewith
KR101994129B1 (en) 2015-05-28 2019-06-28 닥터 레디스 레보러터리즈 리미티드 Celecoxib oral composition for pain treatment
ITUA20164228A1 (en) * 2016-06-09 2017-12-09 Labomar S R L Self-emulsifying and gastro-resistant fat matrix formulation and relative preparation method
PL3500349T3 (en) * 2016-08-22 2022-03-28 Remediation Products, Inc. Bioremediation composition with time-release materials for removing energetic compounds from contaminated environments
US11471415B2 (en) 2017-10-10 2022-10-18 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation and methods of treatment
US10441544B2 (en) 2017-10-10 2019-10-15 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
US10869838B2 (en) 2017-10-10 2020-12-22 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH586568A5 (en) * 1972-04-10 1977-04-15 Hoffmann La Roche
US3962384A (en) * 1972-04-10 1976-06-08 Hoffmann-La Roche Inc. Spray-drying technique for preparing agglomerated powders
JPS5157813A (en) * 1974-11-14 1976-05-20 Sankyo Co Ll dooba mataha sonojudotaiseizaino seiho
SE421042B (en) * 1976-06-29 1981-11-23 Kockums Chem WANT TO REDUCE THE QUANTITY OF BIOLOGICAL ACTIVE SUBSTANCE REQUIRED FOR SOME BIOLOGICAL EFFECT
US4360061A (en) 1980-04-03 1982-11-23 Exxon Research And Engineering Co. Oil recovery process using polymer microemulsion complexes
US4353806A (en) 1980-04-03 1982-10-12 Exxon Research And Engineering Company Polymer-microemulsion complexes for the enhanced recovery of oil
DE3224619A1 (en) 1981-07-14 1983-05-19 Freund Industrial Co., Ltd., Tokyo Oral pharmaceutical composition
FR2594693B1 (en) * 1986-02-24 1990-01-05 Farah Nabil NOVEL PROCESSES FOR THE PREPARATION FROM DRY EMULSIONS OF SOLID ORAL FORMS WITH MODIFIED AND DELAYED RELEASE OF THEIR ACTIVE INGREDIENTS
GB8822857D0 (en) * 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
US5364632A (en) * 1989-04-05 1994-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5688761A (en) 1991-04-19 1997-11-18 Lds Technologies, Inc. Convertible microemulsion formulations
EP0580778B1 (en) 1991-04-19 1999-08-11 LDS Technologies, Inc. Convertible microemulsion formulations
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US5393527A (en) 1993-01-04 1995-02-28 Becton, Dickinson And Company Stabilized microspheres and methods of preparation
US5435936A (en) 1993-09-01 1995-07-25 Colgate Palmolive Co. Nonaqueous liquid microemulsion compositions
ES2094688B1 (en) * 1994-08-08 1997-08-01 Cusi Lab MANOEMULSION OF THE TYPE OF OIL IN WATER, USEFUL AS AN OPHTHALMIC VEHICLE AND PROCEDURE FOR ITS PREPARATION.
SE9503143D0 (en) * 1995-09-12 1995-09-12 Astra Ab New preparation
US5800834A (en) 1996-06-10 1998-09-01 Spireas; Spiridon Liquisolid systems and methods of preparing same

Also Published As

Publication number Publication date
US6280770B1 (en) 2001-08-28
ATE462417T1 (en) 2010-04-15
EP1104290A1 (en) 2001-06-06
EP1104290A4 (en) 2006-01-18
JP2002522473A (en) 2002-07-23
JP4815053B2 (en) 2011-11-16
AU5486899A (en) 2000-03-06
WO2000009093A1 (en) 2000-02-24
DE69942205D1 (en) 2010-05-12
EP2127642A3 (en) 2010-02-24
EP2127642A2 (en) 2009-12-02
EP1104290B1 (en) 2010-03-31
CA2339991C (en) 2007-01-02
ES2341510T3 (en) 2010-06-21

Similar Documents

Publication Publication Date Title
CA2339991A1 (en) Microemulsions as solid dosage forms for oral administration
HUP0000138A2 (en) Controlled-release pharmaceutical compositions containing opioid analgetics
CA2199778A1 (en) Extended release formulation of venlafaxine
CA2213700A1 (en) Pharmaceutical composition for piperidinoalkanol compounds
HUP0302086A2 (en) Oral pharmaceutical composition with a delayed action and process for its preparation
IL116674A (en) Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
CA2427815A1 (en) Controlled release hydrocodone formulations
CA2356380A1 (en) Immunosuppressive effects of pteridine derivatives
WO2001085257A3 (en) Opioid antagonist compositions and dosage forms
CA2326756A1 (en) Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients
HUP0301972A2 (en) Active substance combination containing an opioid having a fentanyl-type structure and ketamine and pharmaceutical compositions containing it
CA2322644A1 (en) Pharmaceutical composition of topiramate
WO2005034908A3 (en) A solid dosage form comprising a fibrate and a statin
RU93004793A (en) HINAZOLIN DERIVATIVES, METHOD OF THEIR PRODUCTION, PHARMACEUTICAL COMPOSITION ON THEIR BASIS
WO2002094774A3 (en) Oxcarbazepine dosage forms
CA2237582A1 (en) Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhibitors
CA2347195A1 (en) Oral pharmaceutical compositions containing buprenorphin
PL348419A1 (en) Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient
BR0111868A (en) Pharmaceutical Compositions
CA2236641A1 (en) Preparation of fagopyritols and uses therefor
CA2489140A1 (en) Dosage form containing pantoprazole as active ingredient
CA2348474A1 (en) Pharmaceutically active composition and dispensing device
CA2078869A1 (en) Pharmaceutical compositions containing ipriflavone, process for the preparation thereof and relative therapeutic use
NO331205B1 (en) Pharmaceutical composition as solid dosage form and method of preparation thereof
CA2376847A1 (en) Complex of eletriptan and a cyclodextrin derivative

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180813